Leerink upgraded Vertex Pharmaceuticals (VRTX) to Outperform from Market Perform with a $456 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals: Strong Market Position and Growth Potential Drive Buy Rating
- Vertex Pharmaceuticals announces CASGEVY reimbursement agreement in Italy
- Vertex Pharmaceuticals: Strong Buy Rating Backed by Promising Pipeline and Strategic Positioning
- Vertex Pharmaceuticals Positioned for Growth with FDA Support for Non-Opioid Analgesics
- FDA Draft Guidance Boosts Vertex Pharmaceuticals’ Prospects for Non-Opioid Analgesics